Management of Early Menopause/Premature Ovarian Insufficiency in Women with or at High Risk of Breast Cancer

Abstract

The global incidence of breast cancer is increasing, as is the efficacy of treatments. Consequently, increasing survival rates reinforce the importance of survivorship issues, including posttreatment menopausal symptoms, sexual function, and mental health and well-being. Breast cancer patients can experience a range of menopausal symptoms associated with their treatment. Most commonly women may experience vasomotor symptoms, including hot flushes and night sweats. Particularly for women on maintenance tamoxifen therapy, up to 80% will experience hot flushes, with almost one-third of these women reporting severe symptoms. Breast cancer patients may also experience genitourinary symptoms of menopause, which may include vaginal dryness and irritation, dyspareunia, and dysuria. Hormonal therapy has long been established as the most effective treatment for vasomotor symptoms. However, the hormonal nature of breast malignancies renders systemic hormone therapies unsuitable for these patients, posing a unique treatment challenge, which may result in clinicians not feeling confident to manage them. Consequently, this review outlines pharmacological and nonpharmacological options for women with bothersome menopausal symptoms after breast cancer treatment and provides practical, evidence-based guidance for clinicians.

Keywords

breast cancer - menopause - early menopause - menopausal hormone therapy

Publikationsverlauf

Artikel online veröffentlicht:
31. März 2021

• References

• 1 Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health 2020; 8 (08) e1027-e1037
• 2 Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015; 18 (04) 483-491
• 3 The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017; 24 (07) 728-753
• 4 Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014; 21 (03) 267-274
• 5 Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms after cancer. Climacteric 2019; 22 (06) 572-578
• 6 Sousa MS, Peate M, Jarvis S, Hickey M, Friedlander M. A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol 2017; 9 (04) 269-285
• 7 Schover LR, Baum GP, Fuson LA, Brewster A, Melhem-Bertrandt A. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors. J Sex Med 2014; 11 (12) 3102-3111
• 8 Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012; 104 (05) 386-405
• 9 Sayakhot P, Vincent A, Deeks A, Teede H. Potential adverse impact of ovariectomy on physical and psychological function of younger women with breast cancer. Menopause 2011; 18 (07) 786-793
• 10 Jin Y, Hayes DF, Li L. et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 2008; 26 (36) 5849-5854
• 11 Jones SE, Cantrell J, Vukelja S. et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol 2007; 25 (30) 4765-4771
• 12 Wills S, Ravipati A, Venuturumilli P. et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract 2012; 8 (03) 144-148
• 13 Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108 (06) 1354-1360
• 14 Crandall CJ, Hovey KM, Andrews CA. et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 2018; 25 (01) 11-20
• 15 Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat 2012; 135 (02) 603-609
• 16 ACOG. ACOG Committee Opinion No. 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol 2016; 127 (03) e93-e96
• 17 Faubion SS, Larkin LC, Stuenkel CA. et al; North American Menopause Society. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018; 25 (06) 596-608
• 18 Management of Menopause after Cancer. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. 2020 . Accessed April 15, 2020 at: https://ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women%27s%20Health/Statement%20and%20guidelines/Clinical%20-%20Gynaecology/Management-of-the-Menopause-after-Breast-Cancer-(C-Gyn-15)-Review-November-2014_1.pdf?ext=.pdf
• 19 Davis SR, Baber R, Panay N. et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab 2019; 104 (10) 4660-4666
• 20 Sismondi P, Kimmig R, Kubista E. et al. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial. Maturitas 2011; 70 (04) 365-372
• 21 Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab 2018; 103 (11) 4146-4154
• 22 Melisko ME, Goldman ME, Hwang J. et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol 2017; 3 (03) 313-319
• 23 Shams T, Firwana B, Habib F. et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014; 29 (01) 204-213
• 24 Speroff L, Gass M, Constantine G, Olivier S. Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111 (01) 77-87
• 25 Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause 2009; 16 (03) 477-483
• 26 Nelson HD, Vesco KK, Haney E. et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295 (17) 2057-2071
• 27 Sun Z, Hao Y, Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol Obstet Invest 2013; 75 (04) 255-262
• 28 Freeman EW, Guthrie KA, Caan B. et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305 (03) 267-274
• 29 Rada G, Capurro D, Pantoja T. et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev 2010; (09) CD004923
• 30 Fisher WI, Johnson AK, Elkins GR. et al. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin 2013; 63 (03) 167-192
• 31 Position statement: non-hormonal management of menopause-associated vasomotor symptoms: 2015 position statement of the North American Menopause Society. Menopause 2015; 22: 1-20
• 32 Pandya KJ, Thummala AR, Griggs JJ. et al. Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat 2004; 83 (01) 87-89
• 33 Pandya KJ, Morrow GR, Roscoe JA. et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005; 366 (9488): 818-824
• 34 Brennan A, Hickey M. Managing the menopause without hormones. Med Today 2020; 21 (02) 50-51
• 35 Boekhout AH, Vincent AD, Dalesio OB. et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2011; 29 (29) 3862-3868
• 36 Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M. Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study. Ann Oncol 2007; 18 (04) 689-693
• 37 Buijs C, Mom CH, Willemse PH. et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 2009; 115 (03) 573-580
• 38 Australasian Menopause Society. Non-hormonal treatments for 686 menopausal symptoms. 2017 . Accessed October, 2020 at: https://www.menopause.org.au/images/stories/infosheets/docs/AMS_Nonhormonal_Treatments_for_Menopausal_Symptoms.pdf
• 39 McCormick CA, Brennan A, Hickey M. Managing vasomotor symptoms effectively without hormones. Climacteric 2020; 23 (06) 532-538
• 40 Mitchell CM, Reed SD, Diem S. et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med 2018; 178 (05) 681-690
• 41 Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol 2015; 33 (30) 3394-3400
• 42 North American Menopause Society. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22 (11) 1155-1172 , quiz 1173–1174
• 43 Mann E, Smith MJ, Hellier J. et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012; 13 (03) 309-318
• 44 Atema V, van Leeuwen M, Kieffer JM. et al. Efficacy of internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Clin Oncol 2019; 37 (10) 809-822
• 45 Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013; (12) CD001395
• 46 Carter J, Stabile C, Seidel B, Baser RE, Goldfarb S, Goldfrank DJ. Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors. J Cancer Surviv 2017; 11 (02) 274-283
• 47 Pagano T, De Rosa P, Vallone R. et al. Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. Menopause 2016; 23 (10) 1108-1113
• 48 Gambacciani M, Levancini M. Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause 2017; 24 (03) 316-319
• 49 Pines A, Sturdee DW, Birkhäuser MH, Schneider HP, Gambacciani M, Panay N. Board of the International Menopause Society. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007; 10 (03) 181-194
• 50 Grossmann M, Ramchand SK, Milat F. et al. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf) 2018; 89 (03) 280-296
• 51 Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14 (01) 78-84
• 52 Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006; 24 (04) 675-680
• 53 Gralow JR. Bone density in breast cancer: when to intervene?. J Clin Oncol 2007; 25 (22) 3194-3197
• 54 Zhu D, Chung HF, Dobson AJ. et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019; 4 (11) e553-e564
• 55 Cheung YM, Ramchand SK, Yeo B, Grossmann M. Cardiometabolic effects of endocrine treatment of estrogen receptor-positive early breast cancer. J Endocr Soc 2019; 3 (07) 1283-1301
• 56 Manickam K, Buchanan AH, Schwartz MLB. et al. Exome sequencing-based screening for BRCA1/2 expected pathogenic variants among adult Biobank participants. JAMA Netw Open 2018; 1 (05) e182140
• 57 New South Wales Health, eviQ 2020. BRCA1 or BRCA2–risk management. Accessed January 2021 at: https://www.eviq.org.au/cancer-genetics/adult/risk-management/3814-brca1-or-brca2-risk-management-female#cancer-tumour-risk-management-guidelines
• 58 Kotsopoulos J, Gronwald J, Karlan BY. et al; Hereditary Breast Cancer Clinical Study Group. Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers. [published correction appears in JAMA Oncol 2018;4(8):1139] JAMA Oncol 2018; 4 (08) 1059-1065